Drug resistance in ovarian cancer-the role of p53

Pathology and Oncology Research

Volumn 4, Issue 2, 1998, Pages 97-102

  Petty, Russel ^a   Evans, Alan ^a   Duncan, Iain ^a   Kurbacher, Christian ^b   Cree, Ian ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenocarcinoma; Bcl 2; Chemotherapy; Immunostaining; Ovary; P53

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; MEGESTROL ACETATE; MELPHALAN; PROTEIN BCL 2; PROTEIN P53; TREOSULFAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE ACTIVATION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PROGNOSIS;

EID: 0031825046     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02904701     Document Type: Article

References (4)

1. Bosari S, Viale G, Radaelli U, et al: p53 accumulation in ovarian carcinoma and its prognostic implications. Hum Pathol 24:1175-1179, 1993.
2. Brown R, Clugston C, Burns R, et al: Increased accumulation of p53 protein in cisplatin-resistant cell lines. Int J Cancer 55:678-684, 1993.
3. Cree IA, Kurbacher CM: Individualising chemotherapy for solid tumors - is there any alternative? Anti-Cancer Drugs 8:541-548, 1997.
4. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.